Paradigm Biopharmaceuticals (ASX:PAR) has marked 2025 as a transformative year, moving from regulatory preparation to the active execution of its global Phase 3 clinical trial for iPPS (Zilosul) in knee osteoarthritis, while also strengthening its financial foundations and broadening its treatment pipeline. …
Adherium pushes ahead with US expansion and stronger commercial focus
August 31, 2025 Australian Biotech
Latest Video
New Stories
-
The regulator that deleted the truth from its answers now wants to police the media
October 1, 2026 - - Latest News -
By the TGA's own test, the Health Minister's press releases are advertising
October 1, 2026 - - Latest News -
Eczema patients who don't respond to steroids get subsidised access to ointment
October 1, 2026 - - Latest News -
Vitrafy takes its frozen platelet push to America's Midwest
September 30, 2026 - - Australian Biotech -
Paradigm Biopharmaceuticals enters voluntary administration after Phase 3 setback
September 30, 2026 - - Australian Biotech -
FDA fast tracks Telix scan that could spare men prostate biopsies
September 30, 2026 - - Australian Biotech -
Australian broadcast personality reveals the scars shingles left behind
September 30, 2026 - - Latest News